A REVIEW ON: ATRIGELâ€“THE MAGICAL TOOL
The widely effective and most common form of drug delivery is parenteral administration for active drug substances with poor bio-availability and the drugs with a narrow therapeutic index. Though parenteral administration of drug is often critical and associated with problems such as limited number of acceptable excipients, stringent requirements of aseptic production process, safety issues, patient noncompliance. Still this route maintains its value due to special advantages like quicker onset of action in case of emergency, target the drug quickly to desired site of action, prevention of first pass metabolism etc. The application of advanced drug delivery technology to parenteral administration lead to development of liposomes, nanosuspensions, solid implants etc. to overcome limitations of conventional parenteral delivery. Solid implants are reported to produce very reproducible release profiles. However, because of their size, they require surgical implantation or the use of large trochars to administer the product. Delivery systems consisting of microparticles can be injected into the body using conventional needles and syringes and have been the most widely accepted biodegradable polymer system for parenteral use. However, the manufacturing processes for microparticles are often complex and difficult to control leading to batch-to-batch product non uniformity. These methods of administration often limit the product's market potential due to patient and physician acceptance issues. Therefore, a delivery system that combines the simplicity and reliability of solid implant devices alongwith convenience and ease of administration of microparticles is desired. In situ gel forming systems represent a desired alternate. This article gives the idea about In situ gel forming system to provide drug release in sustained release manner.
2. Raghanaveen. Parenteral Controlled Drug Delivery System, Pharmainfo. Net; 2009.
3. JR Robinson, VL Lee. Controlled drug delivery: fundamental and applications, marcel dekker, USA; 2003.
4. M Radomsky, L Liu, Z Iwamoto. Sustained release injectable products, interpharm press: Englewood, Colorado; 2000. p. 181-202.
5. L Lachman, HA Lieberman. The theory and practice of industrial pharmacy, CBS publishers, India; 2005.
6. G Gregoriadis. Liposome technology. Vol. 1. Informa health care, USA; 2007.
7. CB Packhaeuser, J Schnieders, CG Oster, T Kissel. In situ forming parenteral drug delivery systems: an overview. Eur J Pharm Biopharm 2004;58:445â€“55.
8. R.L. Dunn, J.P. English, D.R. Cowsar, D. P. Vanderbilt. US patent 4, 938,763; 1990.
9. D. B. Patel, Journal of Global Pharma Technology, 2010, vol2 , 85-90.
10. N. K. Jain, Controlled and Novel Drug Delivery, CBS Publishers, 2008.
11. A. J. Spiegel, Noseworthy, J.Pharm. Sci. 1963, 52, 917-927.
12. M. Rathbone, J. Hadgraft, M. Roberts, Modified Release Drug Delivery Technology,Marcel Dekker, 2003.
13. F. M. Chu, M. Jayson, M. K. Dineen, R. Perez, R. Harkaway, R. C Tyler, J. Urol., 2002, 168 , 1199-1203.
14. R. L. Dunn, J. S. Garrett, H. Ravivarapu, B. L. Chandrashekar, US Patent 6,565,874,2003.
15. A. J. Tipton, W. U. V. Trumpore, R. L. Dunn, US-Japan Symposium on Drug Delivery, 1991, 16â€“20.
16. K. J. Brodbeck, J. R. Desnoyer, A. J. Mchugh, J. Control. Release, 1999, 62 , 333-344.
17. P. D. Graham, K. J. Brodbeck, A. J. Mchugh, J. Control. Release, 1999, 58 , 233-245.
18. H. Kranz, G. A. Brazeau, J. Napaporn, R. L. Martin, W. Millard, R. Bodmeier, Int. J. Pharm., 2001, 212 , 11-18.
19. J. L. Cleland, Injectable Gels for Local and Systemic Delivery of Proteins, Proceedings 28th International Symposium on Controlled Release of Bioactive Materials and Fourth Consumer and Diversified Products Conference, Vol. 1, 2001.
20. B. K. Lowe, R. L. Norton, E. L. Keeler, K. R. Frank, A. J. Tipton, Trans Soc Biomater., 1993, 16-54.